Louis J Summaria

58913939, Apr 6, 1999

Sep 12, 1997

8/945395

Marjorie S. Read - Durham NC
Arthur P. Bode - Greenville NC
Louis J. Summaria - Villa Park IL

The University of North Carolina at Chapel Hill - Chapel Hill NC
Armour Pharmaceutical - Kankakee IL
East Carolina University - Greenville NC

A61L 900

422 31

A method for inactivating microbiological contaminants in a human blood platelet preparation is disclosed. The method comprises, first, providing blood platelets, particularly human blood platelets, suspected of being contaminated with microorganisms. The platelets are then contacted to a fixative for a time sufficient to fix the platelets. After fixing, the platelets are preferably washed and dried to produce fixed-dried platelets. The step of contacting the platelets to a fixative is carried out for a time sufficient to kill some or all the of the contaminating microorganisms.

40826120, Apr 4, 1978

Sep 24, 1976

5/726142

Kenneth C. Robbins - Chicago IL
Louis Summaria - Villa Park IL

Michael Reese Research Foundation - Chicago IL

C07G 7026
A61K 3748

195 62

A functionally active fraction of plasmin is provided which is capable of forming with streptokinase a complex with plasminogen activator activity. The fraction is made by reducing the disulfide bonds of plasmin molecules while inhibiting the serine protease activity of the plasmin and separating the light (B) chain fraction from the reaction product.

61398780, Oct 31, 2000

Apr 27, 1998

9/066694

Louis Summaria - Villa Park IL
Nathan Roth - Bourbonnais IL
Aberash Berhe - Bourbonnais IL
Mark Even - Bourbonnais IL

Aventis Behring, LLC - King of Prussia PA

A61K 3514

424529

A method using diafiltration to prepare a blood product is described. The method removes contaminating plasma proteins from whole blood or blood products. Diafiltration may be used on paraformaldehyde-fixed platelets to remove formaldehyde to undetectable levels, and to suspend the platelets into a formulation buffer suitable for subsequent treatment, such as lyophilization. The manufacturing procedure can be divided into three steps, a first diafiltration, fixation, preferably with paraformaldehyde, and a second diafiltration. In the first step, plasma proteins are removed from fresh or stored platelets or blood cells. The technique is gentle to prevent the activation and aggregation of the platelets. Fixation stabilizes the platelets to withstand freezing, lyophilization and subsequent reconstitution, and also provides a viral and bacterial reduction. The second diafiltration removes the paraformaldehyde to undetectable levels, and suspends the platelets or blood cells into a formulation buffer for subsequent lyophilization.